Myasthenia Gravis

DENVER — Treatment with IV efgartigimod improved functionality for individuals with acetylcholine receptor-positive generalized myasthenia gravis, according to a poster from the American Academy of Neurology annual meeting.

Artificial intelligence-based diagnostic tools may be valuable in accurately tracking myasthenia gravis symptoms and mitigating disease risk, according to a poster at the 2024 MDA Clinical & Scientific Conference.

Most individuals with myasthenia gravis were satisfied with their patient journey, but those who were dissatisfied cited issues with diagnostic delays, side effects of treatment and lack of advisement on approved therapies.

Nipocalimab met the primary endpoint in a pivotal phase 3 trial in patients with generalized myasthenia gravis, as well as in a phase 2 study in adults with Sjögren’s disease, according to topline results released by Johnson & Johnson.

The FDA has granted fast track designation for an autologous, fully human CD19 chimeric antigen receptor T-cell product candidate to treat those with refractory progressive multiple sclerosis, according to the manufacturer.

Nipocalimab showed evidence of dose-dependent, statistically significant symptom reductions in patients with generalized myasthenia gravis, while remaining generally safe and well-tolerated, in a phase 2 trial.

The FDA has granted fast track designation for KYV-101, an autologous, fully human CD19 chimeric antigen receptor T-cell product candidate, to treat myasthenia gravis.

The FDA has approved UCB’s Zilbrysq for the treatment of generalized myasthenia gravis in adults who are anti-acetylcholine receptor antibody positive.

The FDA has approved Rystiggo, a subcutaneous infusion therapy to treat generalized myasthenia gravis in adults who are anti-acetylcholine receptor or anti-muscle-specific tyrosine kinase antibody positive.